Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243243 · ClinicalTrials.gov registry record · Phase 3
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
A Phase 3 study of Burns, sponsored by United States Army Institute of Surgical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00243243: Completed Phase 3 study of Burns, sponsored by United States Army Institute of Surgical Research.
NCT00243243 is a Phase 3 study of Burns that has completed, run by United States Army Institute of Surgical Research. The registered enrollment target is 20 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00243243, a Phase 3 study of Burns, has completed, sponsored by United States Army Institute of Surgical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Recombinant Factor VIIa
Study Locations (1)
Texas
- United States Army Institute of Surgical Research - Fort Sam Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00243243 record still lists
NCT00243243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 83-participant average among 36 other Burns trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00243243 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00243243 about?
NCT00243243 is a clinical study titled "Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn". The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.
What is the current status of trial NCT00243243?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2006-01. Estimated completion is 2011-07.
What conditions does trial NCT00243243 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT00243243?
The interventions under investigation include: Placebo (DRUG), Recombinant Factor VIIa (DRUG).
Who is sponsoring clinical trial NCT00243243?
This trial is sponsored by United States Army Institute of Surgical Research, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00243243 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00243243's enrollment target sits among peer trials
20 23rd of 36 higher than 11 of 36 other Burns trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burns trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
COMPLETED · Phase 3
-
StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
COMPLETED · Phase 3
-
Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery
COMPLETED · Phase 3
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
-
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia